Market Signal Briefing

Bitcoin price has dipped again. The decline comes amid growing investor caution ahead of U.S. inflation data, rising ETF outflows, and massive liquidations.

Summary

Bitcoin price sits at $111,678, down 0.9% on the day.
The crypto giant’s losses come ahead of U.S. inflation data, creating investor uncertainty.
Exchange-traded funds tracking Bitcoin recently recorded outflows reaching $466 million.
If BTC price breaks below $110,000, next support is $108,000.

Bitcoin price has extended its losing streak for the fourth consecutive day, shedding 0.9% in the past 24 hours to trade at $111,678, according to market data crypto.news.

The downturn reflects mounting investor caution as markets brace for key U.S. inflation data, with traders unsure whether the Federal Reserve will lean hawkish or dovish in its next moves. The uncertainty has triggered broad risk-off sentiment, leading many to scale back exposure to Bitcoin (BTC) and other risk assets.

Bitcoin price under pressure amid strong ETF outflows and liquidations
Following the significant $1.7 billion liquidation on Monday, one of the largest of 2025, there has been increased profit-taking among investors who are trying to cut down exposure to Bitcoin. This is further driven by the broader market cooldown, which is making investors more cautious.

Adding to the negative sentiment is a rise in ETF outflows. The U.S.-listed funds tracking BTC posted $466 million in outflows in recent days, outweighing the smaller inflows recorded earlier in the week.

Also, investors are positioning ahead of Friday’s $22.6 billion Bitcoin future options expiry. Historically, Bitcoin tends to experience selling pressure ahead of large expirations, as leveraged positions are unwound and traders hedge risk. A relief rally could follow once the expiry passes and broader uncertainty clears.

Technical indicators show weak momentum
On the technical side, Bitcoin price is now significantly below its September 19 peak near $117,000, forming a descending pattern of lower highs and lower lows, a classic bearish structure. The RSI has dropped to 42.30, signaling waning buying interest, while the MACD has flipped bearish with a growing negative histogram.

Volume remains muted, highlighting indecision from both bulls and bears. If Bitcoin fails to hold above the $110,000 support, a further drop toward $108,000 is likely. However, a recovery above $113,500 could help spark a price rebound.

BTC price chart | Source: crypto.news

Don Burnette, Kodiak AI founder and CEO, joins 'Squawk Box' to discuss the potential benefits of AI powered trucking, how autonomous trucking technology works, rollout expansion timeline, capital requirements, and more.

<div><p>
- <i>Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim analysis data positive -</i></p><p>
- <i>Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin in APOL1-mediated kidney disease; potential to file for accelerated approval in the U.S. if 48-week interim analysis data positive -</i></p><p>
- <i>Phase 2 proof-of-concept study initiated for VX-407 in patients with autosomal dominant polycystic kidney disease -</i></p></div><div>
<p><span>BOSTON--(<a href="https://www.businesswire.com/" target="_blank">BUSINESS WIRE</a>)--</span><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=9b7532fcfcbb83cf0da5730ed359619d" target="_blank">Vertex Pharmaceuticals Incorporated</a> (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). These updates represent significant progress toward reaching the Company’s goal of bringing forward first-in-class or best-in-class therapies that target the underlying cause of these serious kidney diseases.</p><p>
<b><span>Povetacicept in IgAN</span></b>
</p><p>
Vertex announced today that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to povetacicept (pove) for the treatment of IgAN. Pove is an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential in IgAN and other B cell-driven diseases. BTD is for a drug that treats a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on one or more clinically significant endpoints over existing treatments.
</p><p>
Pove is currently being studied in RAINIER, a global Phase 3 clinical trial in patients with IgAN. The study is designed to have a pre-planned interim analysis (IA) evaluating urine protein to creatinine ratio (UPCR) for the pove arm versus placebo after a specified number of patients reach 36 weeks of treatment. The IA cohort has been fully enrolled, and Vertex remains on track to file for accelerated approval in the U.S. in H1 2026 if results are supportive.
</p><p>
<b><span>Inaxaplin in AMKD</span></b>
</p><p>
Vertex also announced today enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD. Inaxaplin is a first-in-class, investigational small molecule inhibitor of APOL1 aimed at addressing the underlying cause of AMKD. The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo. If positive, the IA will serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S.
</p><p>
<b><span>VX-407 in ADPKD</span></b>
</p><p>
The Company also announced it has initiated AGLOW, a Phase 2 proof-of-concept study of VX-407 for the treatment of ADPKD. VX-407 is a first-in-class investigational small molecule corrector that is designed to treat ADPKD in patients with a subset of <i>PKD1</i> variants, estimated at up to approximately 10% of the overall ADPKD population. VX-407 is designed to target the underlying cause of ADPKD by correcting defective PC1 folding to restore function, thereby potentially reducing total kidney volume and preventing progression to kidney failure. AGLOW is a 52-week single-arm study that will evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV) in patients with a subset of variants of the <i>PKD1</i> gene<i>.</i>
</p><p>
“Our pursuit of breakthrough science and serial innovation has changed the treatment landscape for cystic fibrosis, acute pain, sickle cell disease and beta thalassemia by advancing transformative therapies that target the underlying cause of these diseases. We are excited to bring the same level of pioneering science and potentially transformative benefit to patients with serious kidney diseases,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “Today’s announcements on BTD for pove in IgAN, completion of enrollment in the IA cohort in our AMKD study setting up the potential for accelerated approval of inaxaplin and initiation of the VX-407 POC study in ADPKD mark significant milestones toward bringing the next wave of promising medicines to patients who are waiting.”
</p><p>
<b>About IgA Nephropathy (IgAN)</b>
</p><p>
IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan and approximately 750,000 diagnosed patients in China. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years of diagnosis. There are no approved therapies that specifically target the underlying cause of IgAN.
</p><p>
<b>About RAINIER</b>
</p><p>
RAINIER is a global Phase 3 pivotal trial of pove 80 mg administered subcutaneously every four weeks vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating the percent change from baseline in urine protein to creatinine ratio (UPCR) for the pove arm versus placebo after a pre-specified number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104.
</p><p>
<b>About Breakthrough Therapy Designation</b>
</p><p>
The FDA's BTD is intended to expedite development and review of medicines that aim to address a serious condition with preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing treatments on one or more clinically significant endpoints. BTD was granted for pove in IgAN based on data from the Phase 2 RUBY-3 clinical trial.
</p><p>
<b>About APOL1-Mediated Kidney Disease (AMKD)</b>
</p><p>
AMKD is a rapidly progressive, proteinuric kidney disease caused by two variants in the <i>APOL1</i> gene. It occurs in people of African ancestry. AMKD occurs when inherited <i>APOL1</i> genetic variants cause kidney cell injury, cell death and damage to the glomeruli, which filter blood in the kidney. This leads to protein in the urine (known as “proteinuria”) and decreased ability of the kidney to function, which can lead in turn to dialysis, transplant or death. AMKD affects an estimated patient population of approximately 250,000 in the U.S. and Europe, including AMKD patients with comorbidities. There are no therapies currently approved for AMKD.
</p><p>
<b>About AMPLITUDE</b>
</p><p>
AMPLITUDE is a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD. Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care. The primary efficacy endpoint for the final analysis is estimated glomerular filtration rate (eGFR) slope in patients receiving inaxaplin compared to placebo. The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in the eGFR, the onset of end-stage kidney disease or death. The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.
</p><p>
<b>About Autosomal Dominant Polycystic Kidney Disease (ADPKD)</b>
</p><p>
ADPKD is the most common inherited kidney disease and one of the most common severe Mendelian genetic diseases, affecting approximately 300,000 diagnosed people in the U.S. and Europe. As the disease is autosomal dominant, one affected parent can pass on the disease to their children.
</p><p>
In most cases, ADPKD is caused by variants in the<i> PKD1</i> and <i>PKD2</i> genes, which express proteins known as polycystins. The majority of ADPKD patients (~80%) have a variant in the <i>PKD1</i> gene, resulting in a loss of function of polycystin 1 (PC1). This leads to the proliferation of kidney epithelial cells, increased fluid secretion and the formation and expansion of numerous fluid-filled cysts. The progressive cyst formation causes an increase in kidney size and decline in kidney function. Around half of patients with ADPKD experience kidney failure by the age of 60. Kidney cysts can also lead to severe abdominal pain, cyst infection, blood in the urine and kidney stones, all of which significantly impair quality of life. There are no approved therapies that specifically address the underlying cause of ADPKD.
</p><p>
<b>About AGLOW</b>
</p><p>
AGLOW is a global Phase 2 proof-of-concept study of VX-407 for the treatment of ADPKD. It is a single-arm, open-label, 52-week study that will evaluate the effect of VX-407 treatment on height-adjusted total kidney volume (htTKV) in a subset of patients with variants of the <i>PKD1 </i>gene.
</p><p>
<b>About Vertex</b>
</p><p>
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.
</p><p>
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=www.vrtx.com&amp;index=2&amp;md5=fc20c82f0297977f16fcd20116291be7" target="_blank">www.vrtx.com</a> or follow us on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvertex-pharmaceuticals&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=0a488fea606b7e075337526e729dfe1f" target="_blank">LinkedIn</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FVertexPharmaInc&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=0c0cf3b04e512d7110fe9b8a95daf52e" target="_blank">Facebook</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fvertexpharmaceuticals%2F&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=8675a325a0f5559496ddbdba6332206b" target="_blank">Instagram</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2F%40Vertex-Pharmaceuticals&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=0f827cc7619eb9adfa2ef9593dbbff5f" target="_blank">YouTube</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FVertexPharma&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=X&amp;index=7&amp;md5=5121e31387ce8e1131aeb26314f45029" target="_blank">X</a>.
</p><p>
<b>Special Note Regarding Forward-Looking Statements</b>
</p><p>
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Carmen Bozic, M.D., and statements about the expectations for the potential benefits of VX-407 for patients with ADPKD and for the initiated AGLOW study, including study design, expectations for the potential benefits of pove for patients with IgAN, including the preliminary clinical evidence, the study designs for the RAINIER study, and plans to file for accelerated approval in the U.S. in H1 2026 if results are supportive, expectations for the potential benefits of the BTD for pove in IgAN, expectations for the potential benefits of inaxaplin for patients with AMKD, the study designs for the AMPLITUDE study and plans for the IA to serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S., if results are positive, and expectations for the significant progress toward reaching the Company’s goal of bringing forward first-in-class or best-in-class therapies that target the underlying cause of these serious kidney diseases. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that clinical trial data might not be available on the expected timeline, that data from the company's research and development programs may not support registration or further development of its compounds due to safety, efficacy, and other risks, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=06153c31e9f663671067d97f3aad5d63" target="_blank">www.sec.gov</a> and available through the company's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vrtx.com&amp;esheet=54329284&amp;newsitemid=20250925779907&amp;lan=en-US&amp;anchor=www.vrtx.com&amp;index=9&amp;md5=a77434a37fc121ec07fa8b36d7337f8d" target="_blank">www.vrtx.com</a>. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
</p><p>
(VRTX-GEN)
</p></div>

David Bellinger, Senior Analyst at Mizuho Securities, says Costco faces margin pressure despite strong sales and membership. He remains neutral on the stock, favoring Walmart for e-commerce growth.

<div><p><strong>Jim Wyckoff</strong> has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another.</p>
<p>Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a technical analyst for Dow Jones Newswires and as the senior market analyst with TraderPlanet.com. Jim is also a consultant with the highly respected "Pro Farmer" agricultural advisory service. Jim was also the head equities analyst at CapitalistEdge.com. He received his degree from Iowa State University in Ames, Iowa, where he studied journalism and economics.</p>
<p>Follow Jim daily on Kitco.com as he provides both AM and PM roundups and a daily Technical Special.
1 877 963-NEWS
jwyckoff at kitco.com</p></div>

Partnership aligns with Jumia's push for ecofriendly deliveries and sustainable e-commerce KAMPALA, UG / ACCESS Newswire / September 25, 2025 / Jumia (NYSE:JMIA), a leading e-commerce platform in Africa, has partnered with Spiro to launch a fleet of electric bikes (e-bikes) to power deliveries in Uganda, within Kampala. This initiative marks a significant step in Jumia's ongoing Environmental, Social, and Governance (ESG) strategy to reduce carbon emissions and promote sustainable business practices.

JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced it has been awarded a contract from Axiom Space, a leader in commercial space infrastructure, to develop and deliver roll-out solar array (ROSA) wings for Axiom Station's Payload Power Thermal Module (AxPPTM)—the first module for the company's commercial space station. “As a market leader for space power solutions, Redwire is proud to be selected as a.

CEDARHURST, N.Y., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 2,200 properties leased primarily to the United States Postal Service (the “USPS”), ranging from last-mile post offices to industrial facilities, today announced the appointment of Steve Bakke as Executive Vice President, Chief Financial Officer and the Company's Principal Financial Officer effective on or about November 5, 2025. He will be based at the Company's headquarters in Cedarhurst, NY.

Val-d'Or, Québec--(Newsfile Corp. - September 25, 2025) - International Prospect Ventures Ltd. (TSXV: IZZ) (the "Company") announces that, further to its news release of September 24, 2025, it has increased the size of its previously announced non-brokered private placement offering such that it will issue up to 12,000,000 Units at a per Unit price of $0.05 for gross proceeds of up to $600,000 (instead of 7,000,000 Units for gross proceeds of up to $350,000, as previously announced).

Vancouver, British Columbia--(Newsfile Corp. - September 25, 2025) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI"), is pleased to announce plans to carry out a soil geochemical survey program at its wholly-owned Last Chance antimony-gold property, located 18 kilometers west of Kinross Gold's Round Mountain gold mine in south-central Nevada. The survey is scheduled to begin on or around September 29th.

Smart Power for bovine watering pumps at remote Prairie farms Toronto, Ontario--(Newsfile Corp. - September 25, 2025) - Clear Blue Technologies International Inc. (TSXV: CBLU) ("Clear Blue" or the "Company"), the Smart Off-Grid™ Company, is pleased to announce that it is piloting Smart Off-Grid power for a new agriculture application in the Prairies with a Canadian provincial electric utility. Clear Blue will provide systems that enable reliable power in remote Saskatchewan areas for the delivery of water for cattle.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil dry‑powder.

Now worth $20 billion, Oklo has become the largest pre-revenue company listed in the U.S., as investors search for the next big AI trade.

Starbucks on Thursday announced it would close 1% of its corporately owned stores in North America. The company will end the year with nearly 18,300 stores in North America, down from 18,424 in 2024.

BEIJING , Sept. 25, 2025 /PRNewswire/ -- New Oriental Education & Technology Group Inc. ("New Oriental" or the "Company") (NYSE: EDU and SEHK: 9901), a provider of private educational services in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended May 31, 2025 with the Securities and Exchange Commission ("SEC") on September 25, 2025.

Marks and Spencer Group has executed a successful turnaround, with shares up ~400% since 2022, but upside now appears limited. MAKSY's 'Reshape for Growth' plan has delivered strong cash flow, significant debt reduction, and positions the company for future M&A or organic growth. For FY 2026, expect FCF of £420–470 million, a modest dividend yield (~1%), and potential buybacks, with shareholder returns in the low single digits.

- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif. , Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has entered into an agreement with Gossamer Bio, Inc. (Gossamer) (Nasdaq: GOSS) granting Gossamer an option to acquire the Company.

S&P companies that have raised their dividends for shareholders for over 25 years are the kind of investments that passive income investors need to own.

Cardano shows bullish signals with double bottom pattern forming as Foundation backs stablecoin liquidity with eight-figure ADA commitment, targeting 50% rally potential.

The Pi Coin price remains under heavy pressure as the charts highlight a prolonged downtrend. Despite extended weakness, the asset has reached an important technical zone that may influence its short-term direction.

Data shows Bitcoin spot exchange-traded funds (ETFs) have seen netflows flip red, implying a slowdown in demand among institutions. Bitcoin Spot ETFs Have Switched To Net Outflows Recently In a new post on X, on-chain analytics firm Glassnode has discussed about the latest trend in the netflow of the US Bitcoin spot ETFs.

Mechanism Capital co-founder Andrew Kang escalated his critique of Tom Lee's latest Ethereum investment case with an unusually blunt tirade on X, interlacing his rebuttal with a series of sharply worded assertions and data-driven claims. “Tom Lee's ETH thesis is one of the most retarded combinations of financially illiterate arguments I've seen from a well known analyst in a while,” Kang wrote, before listing five pillars he says underpin Lee's view: “(1) Stablecoin & RWA adoption; (2) Digital oil comparison; (3) Institutions will buy and stake ETH; (4) ETH will be equal to all financial infrastructure companies; (5) Technical analysis.

Ethereum has slipped to its lowest level in nearly two months, marking a sharp reversal after weeks of steady accumulation and new all-time highs. According to CryptoSlate data, ETH briefly fell to $3,993 on Sept.

XRP price drops below key support levels as the broader crypto market starts to weaken amidst liquidation-driven selloffs.

Flare Network launches FXRP, enabling XRP holders to participate in DeFi lending, borrowing, and yield farming with $7.1M locked in first day.